CC
MRVI icon

Centiva Capital’s Maravai LifeSciences MRVI Stock Holding History

Centiva Capital’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-30,000
Closed -$72.3K – 1576
2025
Q2 		$72.3K Hold
30,000
– – ﹤0.01% 1418
2025
Q1 		$66.3K Buy
+30,000
New +$119K ﹤0.01% 1428
2024
Q4 		– Sell
-25,000
Closed -$208K – 2143
2024
Q3 		$208K Sell
25,000
-21
-0.1% -$182 ﹤0.01% 1803
2024
Q2 		$179K Sell
25,021
-2,847
-10% -$24.6K ﹤0.01% 1718
2024
Q1 		$242K Buy
27,868
+548
+2% +$3.71K 0.01% 1369
2023
Q4 		$179K Buy
27,320
+2,320
+9% +$15K ﹤0.01% 1459
2023
Q3 		$250K Sell
25,000
-40,914
-62% -$449K 0.01% 1280
2023
Q2 		$819K Buy
+65,914
New +$890K 0.02% 644
2021
Q2 		– Sell
-5,690
Closed -$203K – 1530
2021
Q1 		$203K Buy
+5,690
New +$189K 0.01% 965

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.05B AUM 22.45% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return

Centiva Capital's MRVI Position: Q3 2025 in Review

Centiva Capital sold out of Maravai LifeSciences (MRVI) in Q3 2025, closing a stake of 30,000 shares — an estimated $72.3K sold.

Centiva Capital first reported a position in MRVI in Q1 2021 and held it in 9 quarters. The position peaked at $819K in Q2 2023. 160 funds tracked by Wall St. Rank hold MRVI as of Q3 2025.

  • Centiva Capital reported no remaining Maravai LifeSciences position as of Q3 2025 after selling out during the quarter.
  • Centiva Capital sold 30,000 Maravai LifeSciences shares in Q3 2025, an estimated $72.3K.
  • Centiva Capital first reported a position in Maravai LifeSciences in Q1 2021 and held it in 9 quarters.
  • Centiva Capital's Maravai LifeSciences position peaked at $819K in Q2 2023.
  • 160 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2025.

Based on Centiva Capital's 13F filing for Q3 2025, filed 14 Nov 2025.